Clinical Trial Update: Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating Candonilimab plus Bevacizumab for advanced hepatocellular carcinoma patients who progressed on A+T therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Candonilimab

Snippet

Sponsor: Shi Ming | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN